# Christopher de Souza

> Christopher de Souza is a debt financing investor at Broadview Ventures backing Biotechnology. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures)
- Location: Boston, United States
- Total investments: 11
- Last investment: Apr 2017
- Lead investor: 9%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/cdesouza1

Christopher de Souza is a debt financing investor at Broadview Ventures in Boston focused on Biotechnology and Health Care. Christopher de Souza, PhD, shares responsibility for the day-to-day operations of Broadview Ventures, including business development strategy, identification and screening of new investment opportunities, negotiation of partnering terms and deal structure, as well as portfolio company board involvement. He leverages 20 years of experience inbiopharmaceutical R&D, business development and corporate strategy to help meet the Broadview Ventures mission.Christopher started his pharmaceutical career at Novartis where he was a senior scientist in the Metabolic and Cardiovascular Diseases group and then Director of Strategic Alliances with responsibilities for the therapeutic area strategy, business development and alliance management. After Novartis, Christopher was VP of Business Development at SkyePharma US Inc, a drug delivery company, where he was responsible for out-licensing SkyePharma’s clinical assets and drug delivery technologies. Christopher also founded a business development consulting practice with several clients including JSB-Partners, Diagnostics For All and Metaome.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 73% |
| Health Care | 7 | 64% |
| Therapeutics | 5 | 45% |
| Pharmaceutical | 3 | 27% |
| Medical | 2 | 18% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Debt Financing | 4 | 36% |
| Series A | 3 | 27% |
| Funding Round | 3 | 27% |
| Series B | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 64% |
| Finland | 2 | 18% |
| Denmark | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mellitus | Mellitus is developing a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk, and as a clinical trial test for pharmaceutical development. Its technology is based on the measurement of a novel biomarkercalled Glycated CD59 (GCD59). It was founded in 2011 and is headquartered in Boston, Massachusetts. |  | Debt Financing | Apr 25, 2017 |  |
| Gila Therapeutics | Gila Therapeutics, Inc. is a privately-held Corporation operating in the state of Florida since January 2014, founded by Dr. Andres Acosta and Dr. Sergei Zolotukhin to develop a new therapy for obesity. Gila Therapeutics Inc. uses the discoveries achieved by the company founders to target a new pathway to treat obesity by increasing fullness,decreasing caloric intake and producing weight loss. |  | Series A | Feb 28, 2016 |  |
| Epirium Bio | Epirium Bio is a biopharmaceutical company based in San Diego, is developing a small molecule platform targeting improvements in muscle strength, tissue regeneration, and mitochondrial function. |  | Debt Financing | May 22, 2015 |  |
| Pulmokine | Pulmokine is a privately held biopharmaceutical company. Our focus is on pulmonary disease and kinase inhibitor technology, hence our name Pulmokine. The mission of Pulmokine is to develop new therapies for hard-to-treat lung conditions like pulmonary arterial hypertension (PAH) and related disorders. These include pulmonary arterialfibrosis/interstitial lung disease, sarcoidosis and lung cancer. |  | Debt Financing | Mar 03, 2015 |  |
| Acesion Pharma | Acesion Pharma is a developer of medical drugs designed for the treatment of atrial fibrillation. The company's medical drugs develop treatments for atrial fibrillation which is the most common type of cardiac arrhythmia by following the concept of inhibiting a type of ion channel in heart cells that is involved in generating the electricalsignals that regulate the heart's rhythm, providing consumers with chronic treatment to prevent the recurrence of AF and maintain normal heart rhythm. | $2.5M | Series B | Dec 17, 2014 |  |
| Acesion Pharma | Acesion Pharma is a developer of medical drugs designed for the treatment of atrial fibrillation. The company's medical drugs develop treatments for atrial fibrillation which is the most common type of cardiac arrhythmia by following the concept of inhibiting a type of ion channel in heart cells that is involved in generating the electricalsignals that regulate the heart's rhythm, providing consumers with chronic treatment to prevent the recurrence of AF and maintain normal heart rhythm. |  |  | Dec 17, 2014 |  |
| DecImmune Therapeutics | DecImmune Therapeutics, Inc., a biotechnology company, manufactures drugs for inflammation and autoimmunity. The company was incorporated in 2001 and is based in Boston, Massachusetts. |  |  | Feb 26, 2013 |  |
| Laurantis Pharma | Laurantis Pharma Oy is a specialty pharmaceutical development company with a broad, clinical-stage portfolio in three therapeutic areas: dermatology, ophthalmology, and oncology. Using two proprietary technologies, Laurantis is developing first-in-class products for commercially and medically significant niche indications in these areas. Laurantiswas formed in December 2010 through a merger of the Finnish drug development companies Oy Lx Therapies Ltd and BioCis Pharma Oy. |  |  | Sep 04, 2012 |  |
| Herantis Pharma | Herantis Pharma A pharmaceutical company targeting unmet clinical needs. |  | Series A | Aug 10, 2012 |  |
| Provasculon | Provasculon was founded to exploit the discovery by Richard Lee, MD, a cardiologist at Brigham and Women's Hospital and Associate Professor at Harvard Medical School, and Vincent Segers, MD, a researcher at Brigham and Women's Hospital, of novel forms of the growth factor Stromal Cell-Derived Factor-1 (SDF-1). |  | Debt Financing | Nov 09, 2011 |  |

10 of 11 investments shown.

## Co-investors
- [Argonautic Ventures](https://shizune.co/investors/profile/argonautic-ventures) — VC Fund, 1 deal together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 1 deal together
- [Harvard Business School Angels Chicago](https://shizune.co/investors/profile/harvard-business-school-angels-chicago) — VC Fund, 1 deal together
- [HealthCare Ventures](https://shizune.co/investors/profile/healthcare-ventures) — VC Fund, 1 deal together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 1 deal together
- [Slater Technology Fund](https://shizune.co/investors/profile/slater-technology-fund) — VC Fund, 1 deal together

## About Broadview Ventures

VC Fund · Boston, United States

Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.

5 contacts available at Broadview Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Benjamin Kreitman | Principal | https://shizune.co/investors/profile/benjamin-kreitman |
| Christopher de Souza | Director | https://shizune.co/investors/profile/christopher-de-souza |
| Daniel Gottlieb | Director | https://shizune.co/investors/profile/daniel-gottlieb-b5a0 |
| Maria Berkman | Director | https://shizune.co/investors/profile/maria-berkman |
| Nichole Schiffer | Director of Operations | https://shizune.co/investors/profile/nichole-schiffer |

## Similar investors

### Similar stage
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund
- [The FSE Group](https://shizune.co/investors/profile/finance-south-east) — VC Fund

## FAQ

### What does Christopher de Souza invest in?

Christopher de Souza invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Debt Financing and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Christopher de Souza last invest?

The most recent investment recorded for Christopher de Souza closed in Apr 2017. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co